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Cardiovascular Disease in the Developing World
Prevalences, Patterns, and the Potential of Early Disease Detection
David S. Celermajer, MBBS, PHD,*† Clara K. Chow, MBBS, PHD,*‡§ Eloi Marijon, MD,
Nicholas M. Anstey, MBBS, PHD,¶# Kam S. Woo, MBBS, MD**
Sydney and Darwin, Australia; Paris, France; Hong Kong, China
Over the past decade or more, the prevalence of traditional risk factors for atherosclerotic cardiovascular dis-
eases has been increasing in the major populous countries of the developing world, including China and India,
with consequent increases in the rates of coronary and cerebrovascular events. Indeed, by 2020, cardiovascular
diseases are predicted to be the major causes of morbidity and mortality in most developing nations around the
world. Techniques for the early detection of arterial damage have provided important insights into disease pat-
terns and pathogenesis and especially the effects of progressive urbanization on cardiovascular risk in these
populations. Furthermore, certain other diseases affecting the cardiovascular system remain prevalent and im-
portant causes of cardiovascular morbidity and mortality in developing countries, including the cardiac effects of
rheumatic heart disease and the vascular effects of malaria. Imaging and functional studies of early cardiovas-
cular changes in those disease processes have also recently been published by various groups, allowing consid-
eration of screening and early treatment opportunities. In this report, the authors review the prevalences and
patterns of major cardiovascular diseases in the developing world, as well as potential opportunities provided by
early disease detection. (J Am Coll Cardiol 2012;60:1207–16) © 2012 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.074Globally, cardiovascular diseases (CVDs), which include
coronary heart disease (CHD), strokes, rheumatic heart
disease (RHD), cardiomyopathy, and other heart diseases,
represent the leading cause of death (1). In 2001, it was
estimated that there were 16 million deaths from CVD, but
somewhat surprisingly (given that the vast majority of
studies concerning CVD are carried out in “developed”
regions such as the United States and Western Europe), 13
million of these CVD deaths occurred in low-income and
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012, accepted March 6, 2012.middle-income countries, compared with 3 million in high-
income countries (1). Although CVDs have previously been
characterized as affecting “rich” countries, age-specific rates
of CVD have declined in these areas, while they are
increasing rapidly in many middle-income and low-income
countries. In low-income and middle-income countries, the
proportion of all deaths due to CVD in 2001 was 28%,
compared with 23% in 1990; the corresponding proportions
in developed countries were 39% and 48% (1,2).
Although most CVDs in the world are due to athero-
sclerosis (CHD and ischemic strokes), other CVDs due to
infection (e.g., RHD, Chagas’ heart disease, cardiomyopa-
thy from human immunodeficiency virus (HIV) infection,
cerebrovascular complications of malaria) remain common
in many regions of the developing world (Fig. 1). Early
functional and structural changes of the vessels and/or heart
(before the onset of symptoms and/or advanced disease) are
now detectable in some of these diseases (particularly but
not exclusively by ultrasound) (3,4), and recent studies of
early detection using these modalities have been published
and have provided insights into the early stages of these
disease processes.
Particular challenges in addressing the increasing burden
of CVD in developing countries include low budgets for
health (including for screening, prevention, and treatment),
as well as the education and skill mix of the health
workforce.
cU
m
2
w
b
a
T
f
1208 Celermajer et al. JACC Vol. 60, No. 14, 2012
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disease is appealing in these set-
tings, as many forms of CVD
have long pre-symptomatic phases
during which inexpensive treatment
may improve outcomes (e.g., anti-
biotic prophylaxis in RHD, salt
reduction in hypertension), or
more expensive interventions might
be best reserved for those with
known pre-clinical disease (e.g.,
polypills for subjects at high vas-
cular risk).
Recent developments in non-
invasive or minimally invasive
imaging and diagnostic methods
for studying the heart and ves-
sels, such as portable ultrasound,
raise several interesting possibil-
ities: local workforce training in
diagnosis (and interventions), screening for common and
potentially treatable subclinical diseases, targeted screen-
ing for high-risk patients, and locally relevant research
endeavors.
CVD in developing countries: problems with documentation.
Unfortunately, although the projections for CVD in devel-
oping countries are alarming, there is a paucity of high-
quality data about CVD (or indeed even about risk factor
levels) from many of these countries. The 2001 Global
Burden of Disease Study reported no data available on
causes of death by age and sex for 24.3% of the global
population. Data were unavailable for 0.3% of the popula-
tion in high-income countries but 89.8% of the population
in sub-Saharan Africa, 48.1% in the Middle East and North
Africa, 24.2% in South Asia, and 21.1% in East Asia and
the Pacific (1). Robust national information about the
Abbreviations
and Acronyms
ARF  acute rheumatic
fever
CHD  coronary heart
disease
CV  cardiovascular
CVD  cardiovascular
disease
EMF  endomyocardial
fibrosis
HIV  human
immunodeficiency virus
IMT  intima-media
thickness
NO  nitric oxide
RHD  rheumatic heart
disease
Figure 1 Causes of Cardiovascular Death in 2001, by Region
This figure was created from data from Mathers CD, et al. The burden of disease
Disease and Risk Factors. New York, NY: Oxford University Press, 2006:45–240.prevalence of CVD is also unavailable in many countries (5);
this lack of data is particularly pronounced for disadvan-
taged regions of these countries, such as rural areas or urban
or semiurban poor areas.
Atherosclerotic Cardiovascular Disease
China. DISEASE BURDEN. China is the largest developing
ountry in the world, with a land mass of 9.6 million km2
and a population of more than 1.33 billion. Coronary
disease in China is less prevalent, but stroke prevalence is
much higher compared with most Western developed
countries. In Beijing, the World Health Organization’s
Monitoring Trends and Determinants in Cardiovascular
Diseases age-adjusted annual CHD event rate was 81 per
100,000 men and 35 per 100,000 women in the early 1990s,
compared with age-adjusted CHD mortality rates of 46 per
100,000 men and 26 per 100,000 women in the early 1980s
(6). There was large variation in prevalence between rural
and urban Chinese and between northern and southern
Chinese (7), reflecting interactions of genetic susceptibility,
environmental changes (usually secondary to urbanization),
and increased affluence. With rapid economic transition and
modernization, for example, the rate of CVD events (cor-
onary events plus strokes) increased from 2.3% to 4.4%
annually in the period from 1984 to 1999, for adults aged 35
to 74 years (8).
CHANGING PREVALENCE OF RISK FACTORS. Data from a
SA-PRC Collaborative Study of Cardiovascular Epide-
iology cohort of 9,903 participants followed for 17 years to
000 identified that ischemic CHD and stroke in China
ere positively related to age, current smoking, systolic
lood pressure, serum total cholesterol, diabetes mellitus,
nd body mass index in both Chinese men and women (9).
he population-attributable risk for myocardial infarction
or Chinese male current smokers in the INTERHEART
ortality by condition: data, methods, and results for 2001. Global Burden ofand m
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October 2, 2012:1207–16 CVD in the Developing Worldstudy was 43.6% (95% confidence interval: 38.9% to 48.4%)
(10). Hypertension and smoking were identified as the most
important risk factors for ischemic CVD (including stroke).
Hypertension currently affects 25% of China’s population,
with higher prevalences in cities (25.1%) and urban areas
(17.1%) than in rural areas (15.6%) (11). Chinese men
account for 10% of adults in the world but smoke about 30%
of the world’s cigarettes. Passive smoking is also highly
prevalent (53.5%) among nonsmokers (12).
The prevalences of overweight and hypercholesterolemia
increased steadily by 137% and 88%, respectively, for men
and by 95% and 65%, respectively, for women, over the past
decade (13). Metabolic syndrome is present in 30.4% of
Chinese patients with coronary disease (14). Metabolic
syndrome plus overweight was present in 9.8% to 13.9% of
men and 8.5% to 17.8% of women aged 35 to 74 years from
2000 to 2005, higher in northern than southern Chinese
(15). This rate was even higher (age-adjusted rate 21.2%) in
southern modernized Chinese in Hong Kong (16).
INSIGHTS FROM EARLY IMAGING STUDIES IN CHINA. In a
series of community-based cardiovascular (CV) health sur-
veys in mainland and overseas Chinese (the Chinese Ath-
erosclerosis in Aged and Young studies), we have found
Chinese adults to be less susceptible than whites to age-
related endothelial dysfunction (an early surrogate marker of
atherosclerosis) (17). Westernization or modernization of
Chinese adults was associated with significantly greater
carotid intima-media thickness (IMT), another validated
marker of subclinical atherosclerosis (18). Young Chinese
adults have less evidence of endothelial dysfunction than
young white adults with similar direct or indirect exposure
to cigarette smoke (passive smoking) (19). Westernized
Chinese in Sydney and San Francisco, however, are more
susceptible to the dose-related vascular effects of smoking
(pack-years) and to the impact of low high-density lipopro-
tein cholesterol (19). Taken together, these data indicate a
relative sparing of the damaging CV effects of risk factors in
rural Chinese, which is lost with progressive urbanization.
The impact of lifestyle and occupational changes on
atherogenesis has recently been studied in 475 subjects
living in the Three Gorges territories of the Yangtze River
from 2006 to 2008, where the Three Gorges Dam was built,
leading to rapid changes in occupation and lifestyles for
more than 1 million rural people who were suddenly
displaced to the city. These adults, compared with farmers,
developed greater waist-to-hip ratios, higher blood choles-
terol and triglyceride levels, a 4 times higher prevalence of
metabolic syndrome, and greater carotid IMT (20) over 2 to
4 years.
Overweight and obesity are particular problems in urban
China. We have shown that mild to moderate overweight in
children in Hong Kong is associated with arterial endothe-
lial dysfunction and increased carotid IMT compared with
lean children (21). Fortunately, dietary and exercise inter-
ventions significantly improve such obesity-related signs ofvascular dysfunction in children (22). The adoption of
healthy lifestyles at an early age seems a potentially benefi-
cial strategy for atherosclerosis prevention in China in the
21st century.
India. DISEASE BURDEN. There are relatively few mortality
tudies from India. In 2006, the Global Burden of Disease
tudy reported detailed cause-of-death estimates for the
outh Asian region, based on 2001 data (1). CHD was
eported to be the number 1 cause of death in South Asia,
ccounting for 13.6% of all deaths, and stroke was the
ourth leading cause of death, accounting for 6.8% of all
eaths (1). The largest and most recent study of directly
ollected data on adult (age 25 years) mortality reported
n causes of death in 48,000 urban adults and 32,000 rural
dults from Tamil Nadu, India. This study reported death
ates on the basis of “verbal autopsies” from 1996. For men
ge 35 to 69 years, death rates from all CVDs were 685 per
00,000 and for women of corresponding ages 428 per
00,000 (23). The substantially higher CV death rates in
ndia compared with those reported in China over a similar
ime period may relate to a truly higher CV risk in India (1)
nd/or to differences in the accuracy of case ascertainment,
he definitions of CVD used, and/or reporting methods.
his study also found that 41% of urban male deaths and
7% of urban female deaths were due to CVDs, with
roportions in rural areas of 25% for men and 22% for
omen. In contrast, for South Asians in California, the
roportion of deaths due to CVDs from 1985 to 1990 was
3% for men and 20% for women (24).
CHANGING PREVALENCE OF RISK FACTORS. Historically,
most populations from South Asia have documented low
levels of CV risk factors, particularly blood lipid levels,
diabetes, and hypertension. However, in recent decades, the
prevalence of these risk factors has increased, especially in
urban areas. For example, a survey of 6 major cities in India
including 11,216 participants age 20 years reported a
diabetes prevalence of 12.1% and an impaired glucose
tolerance prevalence of 14.1% (25), in contrast to rates of
diabetes reported in urban studies in the 1970s of 1% to 3%
(26). There is also evidence that diabetes rates are increasing
in rural areas. Recent rural studies from select states have
reported diabetes rates as high as 13% (27). Similarly, rates
of hypertension increased from about 5% in urban areas in
the 1960s to 12% to 15% in the 1990s (28). Recent studies
have also documented high rates of abdominal obesity in
certain urban and rural areas. In our somewhat alarming
survey of rural adults from Andhra Pradesh (n 4,535), the
prevalence of central obesity (waist circumference 90 cm
in men and 80 cm in women) was 26.0%, and the
prevalence of metabolic syndrome ranged from 24.6% to
30.2%, depending on the definitions used (29). The pro-
portion of subjects classified as overweight and obese is even
higher when using recently recommended lower body mass
index cut points for Asian adults (30).
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STUDIES. There are few directly collected data on the
incidence of CHD events in India. However, indirect
comparisons of studies in which CHD incidence was
defined using electrocardiography indicate that incidence
is increasing (5). There is also some indication that CHD
event rates in some regions of India may be higher
compared with established market economies. In a cohort
study of 4,151 participants age 25 to 64 years recruited
in 1990 in Delhi, the incidence of CHD was approxi-
mately 19.7 per 1,000; in comparison, the incidence of
CHD in Oxfordshire in the U.K. at a similar time was of
the order of 3 per 1,000 (31). Some studies have also
shown that South Asians acquire CHD at younger ages
compared with other populations, and this appears to be
explained by their higher levels of risk factors at younger
ages (32).
Our recent study from rural India conducted in 2004 of
345 rural Indians found that carotid IMT, a measure of the
burden of atherosclerotic disease that has been shown to be
predictive of the risk for subsequent vascular events, was
thicker in rural Indians compared with urban Australians
(Fig. 2). This greater thickness was not explained by
differences in CV risk factors between the groups. Our
findings suggest that the vasculature of rural Indians may
respond differently to some key CV risk factors. A particular
susceptibility of South Asian Indians to pre-symptomatic
atherosclerosis was also suggested in a study of Anand et al.
(33) in 2000, examining carotid IMT in South Asian and
Chinese immigrants to Canada. The finding of suscep-
tibility to atherosclerotic risk factors in populations with
rapid changes in their environments leading to exposure
to risk factors is similar to that seen in a number of other
migrant studies, such as of South Asians to the United
Kingdom (34).
Africa. In sub-Saharan Africa, there is increasing evidence
of a changing disease profile from infectious diseases and
nutritional deficiencies to noncommunicable chronic dis-
eases, including chiefly CVD (35). Even after incorporating
recent estimates for the spread of HIV/acquired immune
deficiency syndrome, projections of mortality and burden of
Figure 2 Cardiovascular Testing in Rural India for Cardiovascul
and Carotid Intima-Media Thickness, a Surrogate Marker odisease suggest that by 2030, CVD will become the leading
cause of death in low-income countries in Africa, contrib-
uting 13.4% of total deaths, compared with 13.2% from
HIV/acquired immune deficiency syndrome. In addition,
CHD is projected to rank fifth among the 10 leading causes
of disability-adjusted life-years lost in low-income countries
by 2030 (35).
A major factor in the increasing prevalence of atheroscle-
rotic CVD in developing countries is the ongoing change in
nutrition patterns, with progressive shifts to a westernized
diet high in saturated fats and sugar, along with a more
sedentary lifestyle. Furthermore, cigarette consumption is
increasing significantly in most African countries (36). Also,
hypertension is a major risk factor for CVD, particularly
stroke, in sub-Saharan Africa, with an estimated prevalence
of hypertension in adults of 30% (37).
Risk factors for CVD were examined in the INTERHEART
Africa study, an international, standardized, case-control
study that recruited 578 cases of first-time myocardial
infarction and 785 controls from 9 sub-Saharan African
countries (38). The participants, almost 75% of them men,
included 36.3% black Africans, 46.7% colored Africans, and
17% European and other African peoples. Hypertension
and diabetes stand out as particularly important in the black
African population because of its higher population-
attributable risk compared with that observed in the two
other ethnic groups.
Although the major coronary risk factors in Africa are
similar to those identified in other regions of the world,
definitive data from Africa on the magnitude of the burden
of CVD and CV risk factors, the strength of the associations
among the various risk factors, and the incidence of myo-
cardial infarction have generally been lacking. The
INTERHEART Africa study represents presently the largest
comprehensive study carried out in Africa. Even then, more
than 80% of subjects enrolled in this study were from South
Africa, known to be significantly more developed than the
other countries of sub-Saharan Africa. This should caution
against the generalization of these findings to the African
continent overall.
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Heart failure in the developing world is due mainly to
nonischemic causes; hypertensive heart disease, valvular and
myocardial damage from rheumatic fever, and heart muscle
diseases caused by certain infectious agents. These diseases
include HIV cardiomyopathy (recently reviewed in detail
elsewhere) (39) and certain region-specific cardiomyopa-
thies, such as endomyocardial fibrosis (EMF) in Africa and
Chagas’ disease in Latin America, reviewed in the following
discussion. Alcohol, thiamine deficiency, and peripartum
cardiomyopathy are also well-recognized causes of heart
failure in developing nations. Except where noted in the
following, prevalence data for these causes of heart failure
are often unavailable, and population-based studies in this
regard are needed.
RHD. WORLDWIDE BURDEN. RHD accounts for most of
the CV mortality and morbidity among young people in
developing countries, with clinically apparent disease affect-
ing about 20 million people and responsible for an estimated
250,000 premature deaths each year (40). Considering
subclinical disease as well, the prevalence of RHD is likely
2 to 3 times higher than these estimates.
RHD is the result of valvular damage (and less frequently
myocardial and/or pericardial involvement), caused by an
immune response to group A streptococcal infection. Anti-
genic mimicry in association with an abnormal immune
response is the cornerstone of pathophysiology. Acute
rheumatic fever (ARF) classically occurs 3 weeks after
streptococcal pharyngitis and can involve the joints, skin,
brain, and heart. During ARF, about 50% of patients
present with clinical carditis, with an audible cardiac mur-
mur. The incidence of ARF, difficult to assess accurately in
most developing countries, varies from 5 to 80 per 100,000
of the total population (41). Valve dysfunction in RHD
most often develops insidiously after repeated or persistent
ARF attacks (42).
EARLY DETECTION AND PREVENTION. RHD is the result of
preventable disease, as demonstrated by its exceedingly
ow prevalence in nonindigenous populations of developed
ountries. Prevention thus includes improvement of socio-
conomic conditions with better hygiene and housing (pri-
ordial prevention), primary prevention through antibiotic
reatment of streptococcal pharyngitis, and finally secondary
revention of ARF recurrence by penicillin prophylaxis
gainst repeated or chronic ARF attacks.
In the 1970s and 1980s, large screening programs in
choolchildren were recommended by the World Health
rganization and undertaken, in which diagnosis was based
n clinical examination. However, cardiac auscultation may
rove insensitive, especially for early disease. Small regurgi-
ant volumes, especially posteriorly directed mitral regurgi-
ation, simply may not be audible. Furthermore, functional
urmurs are very common in children, especially in theresence of fever or anemia, as may be the case duringommon comorbidities in these regions, including malaria
r sickle cell episodes. In a stepwise screening program
onducted in Tonga, junior and experienced physicians’
uscultation skills were compared (43). Whereas more
xperienced physicians had much higher specificity for
etecting pathologic RHD murmurs, at least half the true
ases of RHD were missed (43).
The emergence of echocardiography (including portable
ystems) as a means of detecting subclinical carditis has
llowed more detailed assessment of subclinical RHD, and
chocardiography may become a valuable tool in early
etection (Fig. 3). In Cambodia and Mozambique, we have
ocumented case detection rates by echocardiography that
ere 3 to 10 times higher than that that found by clinical
xamination among schoolchildren (44). (Fig. 4). Similar
esults have been observed by others (43). The likelihood
hat these subclinical changes are of pathologic significance
s supported by recent data from New Zealand (45) dem-
nstrating that such valve changes (even those considered
inimal) were more frequent among high-risk populations.
CONTROVERSIES AND UNANSWERED QUESTIONS. Al-
though echocardiography may prove a valuable tool in
detecting cases at an early stage, fundamental issues remain
unanswered: 1) the lack of standard echocardiography cri-
teria to diagnose subclinical RHD; 2) the management of
patients with mild valvular abnormalities; and 3) the prac-
ticalities of delivering echocardiographic screening pro-
grams (46).
Changes in echocardiographic criteria considerably alter
the apparent RHD prevalence in screening surveys (47), also
illustrating the difficulties in diagnosing subclinical RHD.
Standardization of echocardiographic criteria is currently
under way, by an international group of the World Heart
Federation (48). Intuitively, secondary prophylaxis may
prove most beneficial at the early stage of RHD, when valve
damage is minimal, but this requires further research. In
Figure 3 Echocardiogram Showing Early,
Subclinical Rheumatic Heart Disease
The regurgitant flow across the mitral valve is shown in blue.
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only in cases of definite subclinical RHD.
EMF in the tropics. EMF is a neglected tropical disease
that predominates in tropical and subtropical areas, affects
mainly children and young adults of low socioeconomic
status, and is recognized as an important cause of heart
disease in Africa, India, and Brazil. First described in
Figure 4 Echocardiography Detects Significantly More Early
Rheumatic Heart Disease Than Clinical Examination
Reprinted, with permission, from Marijon et al. (46).
Figure 5 A Young Male Patient With Restrictive Cardiomyopat
and a Typical Echocardiogram Showing Endomyocardial FibUganda 70 years ago, EMF remains a somewhat mysterious
and understudied disease entity (49). The distinctive patho-
logic feature of established EMF is endocardial thickening
of 1 or both ventricles, more prominent at the apices and the
inflow tracts, usually causing dysfunction of the atrioven-
tricular valves, leading to restrictive ventricular filling and
giant atria (Fig. 5). Rare epidemiologic studies have shown
a very heterogenous distribution of the disease, with some
areas having an extremely high prevalence (for unclear
reasons) (50). For example, in the first large community
echocardiography-based study carried out by the Maputo
Heart Institute 100 miles north of Maputo, Mozambique,
an area known to be endemic for EMF (50), the investiga-
tors demonstrated a prevalence of EMF in the community
of 20% (markedly higher than the 9% previously found in
the same area, using clinical criteria but without echocardi-
ography) (51). The availability of portable echocardiography
thus now provides the opportunity for early diagnosis and
prospective studies in affected communities, which could
ultimately allow better understanding of the natural history
of the disease.
The pathogenesis of EMF remains unknown. Several
hypotheses have been proposed and explored, including
cardiotoxicity of the eosinophil, infectious agents, autoim-
mune processes, genetic predisposition, ethnicity, diet, and
possible chemical factors. Echocardiography is now the
standard technique for the diagnosis of this condition. The
lack of association, however, between clinical and echocar-
diographic findings in EMF has previously been recognized
and may partly explain the late presentation of patients in
hospital-based series and why the diagnosis of EMF is
m Endomyocardial Fibrosishy Fro
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failure or its complications are already present and patients
are thus more difficult to treat (with standard heart failure
medications). Further study is required to know if early
detection by echocardiography can facilitate early diagnosis,
treatment, and possibly improved outcomes in this poten-
tially devastating disease.
Chagas’ disease in Latin America. Chagas’ disease is
endemic to Latin America and can result in cardiomyopathy
during its chronic phase. The causative infection is usually
acquired during childhood; the relevant organism Trypano-
soma cruzi penetrates the skin or eye mucosa of people
usually living in poor rural housing. Acute Chagas’ disease is
usually asymptomatic or presents as a nonspecific febrile
illness. Acute myocarditis is rare in this phase. The chronic
stage occurs decades later, and cardiac pathologic findings
include mononuclear infiltrates, fibrosis, and myocytolysis
(52). Complications include symptomatic left ventricular
systolic and/or diastolic dysfunction and arrhythmia.
Disease control programs have significantly reduced the
number of infected subjects, from approximately 16 million
to 18 million in the early 1990s to 10 million to 12 million
in the early 2000s (53). A substantially larger number (tens
of millions), however, remain at risk for acquiring the
pathogenic infection.
Chagas’ disease in the chronic phase is diagnosed on
serologic testing in patients who grew up in affected areas,
and cardiac involvement is suspected when electrocardiog-
raphy shows atrioventricular block, right bundle or left
anterior hemiblock, and/or multifocal ventricular ectopic
beats.
Echocardiography is extremely valuable in detailed char-
acterization of cardiac involvement in chronic Chagas’
cardiomyopathy, but no screening studies have yet been
reported from community-based samples in endemic areas.
Recent publications, however, have focused on the early
identification of subjects with cardiac involvement, reason-
ing that this may lead to earlier treatment and thus
potentially better outcomes. Heart failure and arrhythmias
are treated along similar lines as other nonischemic cardio-
myopathies, but the therapeutic role of antiparasite therapy
in the chronic phase remains uncertain.
Garcia-Alvarez et al. (54) studied 54 patients and 44
controls and found that diastolic dysfunction (from mitral
inflow and tissue Doppler measurements) and brain natri-
uretic peptide measurements were valuable in early case
detection. Acquatella (53) reviewed relevant publications in
this area in 2007 and concluded that echocardiographic
results in those with positive serologic findings and electro-
cardiographic changes were frequently abnormal, often
markedly so, even in asymptomatic subjects.
This common cause of potentially serious cardiac disease
in Latin America is therefore only poorly studied. On the
basis of published data, echocardiography should be under-
taken in subjects with serologic evidence of disease and
electrocardiographic findings suggestive of abnormality. eMalaria. Although it may not be immediately apparent
why malaria is included in a review of CVD in developing
countries, many of the pathogenic events in severely affected
patients are due to the consequences of microvascular
occlusion and consequent ischemia, as outlined in the
following discussion. Therefore, in that sense, malaria is an
important worldwide cause of “vascular disease” (although
not of classic coronary or carotid artery disease).
WORLDWIDE BURDEN. Although the incidence of malaria
as fallen recently with intensified malaria control measures,
n estimated 2.3 billion people remain at risk for infection
ith Plasmodium falciparum (55), the most pathogenic
pecies causing malaria. P. falciparum causes 350 million to
50 million infections (55) and most of the estimated
80,000 deaths from malaria each year. The majority of
eaths arise from complications of tissue ischemia: meta-
olic acidosis, acute renal failure, respiratory distress, and
ultiple organ failure (56).
PATHOGENESIS OF FALCIPARUM MALARIA AND THE ROLE
OF VASCULAR DYSFUNCTION. A central process in the
athogenesis of severe falciparum malaria is the cytoadher-
nce of parasitized red blood cells to the endothelium,
esulting in microvascular sequestration and obstruction,
hereby causing tissue hypoxia and injury (57). Evidence
ncludes autopsy studies in both adults and children (57)
nd clinical studies showing the obstruction of blood flow in
oth retinal (58) and rectal capillaries. Sequestration of
arasitized red cells is exacerbated by concurrent endothelial
ctivation (59).
Although the histopathologic evidence for microvascular
bstruction in severe malaria dates back to the 19th century
60), the importance of vascular dysfunction in impaired
icrovascular perfusion has only recently been shown in a
eries of studies by our groups (61). Our recent studies in
dults with severe and falciparum malaria have shown
rofound endothelial dysfunction associated with measures
f impaired microvascular perfusion (61), which improves
ith clinical recovery (62). Endothelial dysfunction in
evere malaria is associated with impaired nitric oxide (NO)
ioavailability, which results from hypoargininemia (L-
rginine being the substrate for the enzyme synthesizing
O) (61), increased circulating concentrations of the NO
ynthase inhibitor, asymmetric dimethyl arginine, reduced
xpression of NO synthase 2, and NO quenching due to
alaria-associated intravascular hemolysis (63). As well as
unctional effects on microvascular vasomotor regulation
nd perfusion, reduced endothelial NO bioavailability re-
ults in increased endothelial intercellular adhesion
olecule-1 expression (64) and increased endothelial cell
eibel-Palade body exocytosis (59,65), with concentrations
f the Weibel-Palade body products, angiopoietin-2, and
on Willebrand factor being increased in severe and fatal
alaria and inversely related to endothelial function (59).
ngiopoietin-2 sensitizes endothelium to cytokine-inducedxpression of endothelial adhesion molecules, and von
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mediated parasite cytoadhesion, with both linked to in-
creased microvascular obstruction by parasitized red cells.
EARLY DETECTION OF VESSEL DYSFUNCTION AND
THERAPEUTIC IMPLICATIONS. Noninvasive measures of
endothelial and microvascular dysfunction have proven use-
ful in providing proof of principle for candidate adjunctive
agents targeting the endothelium in malaria and in identi-
fying agents suitable for evaluation in larger clinical trials in
severe malaria (61). Traditional gold-standard measures
such as flow-mediated dilation are operator dependent and
are logistically difficult in critically unwell patients in pe-
ripheral health facilities in malaria-endemic regions. A
portable, operator-independent method, reactive hyperemia
peripheral artery tonometry, is at least 50% dependent on
NO production and has been used as a measure of endo-
thelial function in a number of disease settings (66),
including malaria (61). Because of the importance of vas-
cular dysfunction in the pathogenesis of severe and fatal
malaria (61), noninvasive measures of endothelial and mi-
crovascular dysfunction in patients presenting with severe
malaria may prove to have a role identifying those with the
greatest impairment of vessel dysfunction who may benefit
most from adjunctive agents.
RATIONALE FOR ADJUNCTIVE THERAPIES. An important
recent advance in the treatment of severe malaria has been
the demonstration in 2 large randomized trials that the use
of the most rapidly active antimalarial agent, artesunate,
reduces case fatality in severe malaria in both adults and
children. The results of these studies have changed global
treatment policy from quinine to artesunate (67). Despite
this major advance with antiparasitic drugs, there is no
survival benefit in adults in the first 48 h (68), suggesting
that additional therapies targeting underlying pathogenic
processes are needed to further improve outcomes in this
vital early time window. Although results of limited trials of
adjunctive therapies to date have been disappointing, none
have specifically targeted the endothelium or endothelial
dysfunction. The ability of L-arginine to improve NO
bioavailability and endothelial dysfunction in patients with
moderately severe malaria (61) and its initial safety profile in
malaria (69) have suggested the potential role of agents that
increase NO bioavailability and/or endothelial function in
severe falciparum malaria (61). Trials of L-arginine and
inhaled NO in severe malaria are therefore in progress in
Asia and Africa.
Conclusions
The burden of CVD is increasing sharply in developing
countries, chiefly because of atherosclerosis-related illnesses.
Data from China implicate urbanization, westernization of
diet, and increasing rates of smoking, obesity, and diabetes
in disease pathogenesis. Data from India suggest a possible
particular susceptibility of South Asians to the atherogeniceffects of metabolic risk factors. The paucity of epidemio-
logic data from these and many other poorer countries limits
our knowledge, however, of CVD patterns and prevalence.
In addition, infectious and post-infectious illnesses re-
main common in developing countries, and many affect the
heart and vessels. These diseases include RHD and malaria,
and these impose a considerable burden of CVD on regions
with relatively low per capita health budgets.
New developments in the noninvasive study of cardiac
and vascular structure and function, particularly with ultra-
sound, have provided novel and valuable insights into the
early stages of atherosclerotic, rheumatic, malarial, and
cardiomyopathic diseases in affected regions, including in
rural and remote settings. Such information has informed
concepts about disease prevalences and pathogenesis and in
some cases facilitated the possibilities of pre-symptomatic
screening, early diagnosis, and potentially lifesaving early
therapeutic intervention.
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